Allurion Technologies, Inc. (NYSE: ALUR) (the “Company” or “Allurion”), a pioneer in metabolically healthy weight loss, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,659,565 shares of common stock, issued by the Company on January 27, 2025 (the “January 2025 Warrants”), February 20, 2025 (the “February 2025 Warrants”) and November 12, 2025 (the “November 2025 Warrants” and together with the January 2025 Warrants and the February 2025 Warrants, the “Existing Warrants”), at a reduced exercise price of $1.15 per share. The shares of common stock issuable upon exercise of the January 2025 Warrants and February 2025 Warrants are registered for resale pursuant to the effective registration statement on Form S-3 (File No. 333-286837) and the shares of common stock issuable upon exercise of the November 2025 Warrants are registered for resale pursuant to the effective registration statement on Form S-3 (File No. 333-292660). The aggregate gross proceeds from the exercise of the Existing Warrants is expected to total approximately $3.0 million, before deducting financial advisory fees. The closing of the offering is expected to occur on or about February 25, 2026, subject to satisfaction of customary closing conditions.
The U.S. Food and Drug Administration has granted premarket approval for Allurion’s Gastric Balloon System with the swallowable Allurion Smart Capsule.
Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket approval (PMA) application for the Allurion Gastric Balloon System, featuring the Allurion Smart Capsule.
Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced a partnership with Bionut, a leader in obesity care in Argentina, and Farmastar, a local pharmacy partner with access to the official supplier of Mounjaro (tirzepatide) in Argentina, to provide patients with access to discounted Mounjaro to be used in combination with the Allurion Smart Capsule.
Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced preliminary, unaudited results for the fourth quarter and full year 2025. Management expects preliminary, unaudited results for the period as follows:
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced initial results on the combination of the Allurion Program with low-dose tirzepatide therapy to optimize muscle mass and GLP-1 adherence.
Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced the publication of a peer-reviewed, case-controlled study on the use of the Allurion Smart Capsule combined with lifestyle intervention compared to lifestyle intervention alone and its impact on weight loss and body composition.
Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced a strategic distribution partnership with ProSurg Medical, a leading Brazilian medical device company specializing in bariatric and obesity care. This new partnership draws upon ProSurg Medical’s 30-year experience in the Brazilian market and reflects Allurion’s commitment to establishing a new standard of care in obesity management focused on metabolically healthy weight loss.
Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced its financial results for the third quarter and provided a business update.
Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a pioneer in metabolically healthy weight loss, today announced it has passed critical milestones in the U.S. Food and Drug Administration (the “FDA”) Pre-Market Approval (“PMA”) process for the Allurion Smart Capsule.
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced that it will report financial results for the third quarter 2025 on Wednesday, November 12, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET.
Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced the publication of the first peer-reviewed study on the consecutive use of the Allurion Smart Capsule, a first of its kind, swallowable, procedure-less weight-loss device.
Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced its participation in the ROTH 4th Annual Healthcare Opportunities Conference, which will be held on October 9, 2025 at the Metropolitan Club in New York City. Management will hold one-on-one meetings with investors throughout the day.
Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced its financial results for the second quarter and provided a business update.
